Lucentin / Investor perspective
Lucentin was developed by a surgeon and engineer to connect clinical work valuation with outcome-based payment evaluation. Our commercial strategy starts with paid pilots in hospital service lines, with expansion tied to product value and delivery economics.
The investment thesis
Clinical, operational, and financial leaders need a shared basis for decisions about care. Lucentin brings clinical work valuation and outcome-payment evaluation into that conversation. Our investment thesis centers on a defined institutional buyer, a paid pilot tied to a management decision, and a route to repeat use.
A service-line sponsor needs to reconcile clinical contribution with operational and financial priorities. The initial use case brings physician leadership and finance into a shared review of clinical work, documentation questions, and the decision at hand.
Our initial target is a health-system service-line sponsor working with clinical and financial leadership. One organizational decision defines the scope of the paid pilot and the people responsible for reviewing its results.
Hospital perspective ↗The expansion strategy targets additional service lines and payer-provider care programs. Documented customer value, repeat use, and sustainable delivery economics determine the next account or program.
Insurer perspective ↗Market context / Sources checked October 28, 2026
CMS’s national expenditure estimate provides context for the scale of spending on care.
Source: CMS NHE Fact Sheet ↗AHA’s 2026 edition, based on 2024 survey data, describes the community-hospital landscape. System-level purchasing shapes the actual buyer universe.
Source: AHA Fast Facts 2026 ↗CMS’s January 2026 estimate spans ACOs and specified Innovation Center models, illustrating the reach of care models concerned with cost and quality.
Source: CMS participation highlights ↗The addressable business starts with eligible organizations and annual contract value. Customer discovery and paid pilots are the basis for validating budget ownership, pricing, purchasing requirements, and delivery capacity.
The figures above describe the healthcare landscape. Lucentin’s revenue opportunity is a separate calculation based on target-account counts, validated pricing, and realistic adoption.
Commercial strategy
Use a private demonstration to identify a specific institutional question and the clinical and financial participants who own the decision.
Agree on scope, fee, review responsibilities, and a written decision brief. Evaluate the usefulness of the workflow and the effort required to deliver it.
Illustrative use case and report ↗The goal is recurring institutional use and expansion across relevant programs. Continued use follows a documented customer decision, with pricing and delivery requirements defined for the next engagement.
Milestones for venture diligence
Establish institutional sponsorship, budget ownership, and a funded evaluation tied to a specific decision.
Measure decision usefulness, reviewer feedback, and time to a meaningful result in the selected use case.
Track implementation effort, support needs, and time to value. Build a delivery model that supports additional customers without a proportional increase in custom work.
Validate contract value against acquisition, implementation, and support costs. Track procurement timelines and conversion from pilot to continued use.
Demonstrate sustained institutional use and a clear reason to extend the workflow to another service line or program.
Examine product differentiation, IP ownership and scope, team capabilities, and the resources required to reach the next commercial milestone in private diligence.
Positioning and adoption
EHR reporting, revenue-cycle tools, analytics, and manual clinical-financial review are relevant comparison points. Buyers will assess Lucentin against the process they already use.
Lucentin connects clinical work valuation with outcome-payment evaluation, informed by firsthand surgical and engineering experience. Evaluate that approach against the institution’s current process.
A clear buyer, an important organizational decision, and manageable implementation requirements anchor the adoption case. Workflow fit and delivery economics guide the commercial plan.
Meet the founder
Surgeon. Engineer. Founder & CEO. Amir Nasir brings firsthand clinical practice and surgical leadership experience to the relationship between care delivery, documentation, and reimbursement. Lucentin was developed from that insider perspective, with a mission to transform how clinical contribution and value are understood.
Read the founder story ↗Continue the discussion
Meet the founder to review the product, target customer, commercial strategy, and next investment milestones. Proprietary methods and confidential business information are reserved for private diligence.
Private Demonstration30 minutes via Google Meet.